Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

The a2 Milk Company Limited

ABN

97 769 415 292

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	*Class of *securities issued or to be issued	Time-based rights, each representing an entitlement to acquire ordinary shares in the entity.
2	Number of <sup>+</sup> securities issued or to be issued (if known) or maximum number which may be issued	Time-based rights – 93,809
3	-	

<sup>+</sup> See chapter 19 for defined terms.

		Company Limited at the relevant vesting date, being: (a) in respect of the first 31,270 time-based rights on 1 August 2019; (b) in respect of the next 31,270 time- based rights on 1 August 2020; and (c) in respect of the remaining 31,269 time-based rights on 1 August 2021.
4	<ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they do</li> <li>the extent to which they do interest payment</li> </ul> </li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	No. Any share issued upon vesting of a time-based right will rank equally in all respects with the existing class of quoted ordinary shares from the date of allotment and issue of those shares.
5	Issue price or consideration	Nil.
6		The time-based rights have been granted to the Chief Scientific Adviser (previously, the Chief Scientific Officer) of the entity as part of the on-going long term incentive arrangements that the entity has adopted to assist in the reward, retention and motivation of its employees and relevant contractors.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the</i> <i>subject of this Appendix 3B,</i> and comply with section 6i	No.

<sup>+</sup> See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	n/a
6с	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	n/a
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	n/a
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	n/a
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	n/a
6g	If <sup>+</sup> securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the <sup>+</sup> issue date and both values. Include the source of the VWAP calculation.	n/a
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	n/a

<sup>+</sup> See chapter 19 for defined terms.

7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and <sup>+</sup>class of all <sup>+</sup> <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

	Number	+Class
11 X	730,039,067	fully paid ordinary shares
n		

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in	9,100,998	options issued on 17 August 2015 with an
	section 2 if applicable)	3,300,000	exercise price of NZ\$0.63 options issued on 30 March 2015 with an exercise price of NZ\$0.63
		1,500,000	partly paid ordinary shares
		815,000	performance rights issued on 8 February 2017
		87,000	performance rights issued on 10 March 2017
		406,000	performance rights issued on 28 September 2017
		304,200	performance rights issued on 6 March 2018
		245,787	performance rights issued on 13 July 2018
		599,254	time-based rights issued on 13 July 2018
		93,809	time-based rights issued on 1 August 2018

3 August 2018

10 Dividend policy (in the case of a n/a trust, distribution policy) on the increased capital (interests)

<sup>+</sup> See chapter 19 for defined terms.

# Part 2 - Pro rata issue

11	Is security holder approval n/a required?
12	Is the issue renounceable or non-n/a renounceable?
13	Ratio in which the <sup>+</sup> securities will n/a be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the n/a offer relates
15	<sup>+</sup> Record date to determine n/a entitlements
16	Will holdings on different registers n/a (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in n/a relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents       n/a         Note: Security holders must be told how their entitlements are to be dealt with.       Cross reference: rule 7.7.
19	Closing date for receipt of n/a acceptances or renunciations
20	Names of any underwriters n/a
21	Amount of any underwriting fee or n/a commission
22	Names of any brokers to the issue n/a

<sup>+</sup> See chapter 19 for defined terms.

23	Fee or commission payable to the broker to the issue	n/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	n/a
25	If the issue is contingent on security holders' approval, the date of the meeting	n/a
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	n/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	n/a
28	Date rights trading will begin (if applicable)	n/a
29	Date rights trading will end (if applicable)	n/a
30	How do security holders sell their entitlements <i>in full</i> through a broker?	n/a
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	n/a
32	How do security holders dispose of their entitlements (except by sale through a broker)?	n/a
33	<sup>+</sup> Issue date	n/a

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of \*securities (*tick one*)
(a) \*Securities described in Part 1
(b) All other \*securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible

#### Entities that have ticked box 34(a)

securities

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

- If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories
   1 1,000
   1,001 5,000
   5,001 10,000
   10,001 100,000
   100,001 and over
- 37

A copy of any trust deed for the additional <sup>+</sup>securities

#### Entities that have ticked box 34(b)

- 38 Number of \*securities for which \*quotation is sought
- 39 <sup>+</sup>Class of <sup>+</sup>securities for which quotation is sought



<sup>+</sup> See chapter 19 for defined terms.

40 Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?

If the additional <sup>+</sup>securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another <sup>+</sup>security, clearly identify that other <sup>+</sup>security)

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

	Number	+Class
es		
ne		

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Date:
	(Director/Company secretary)

Print name:

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	n/a
Add the following:	n/a
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	
Note:	
<ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> </ul>	
<ul> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>	
<ul> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<i>Subtract</i> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	n/a
"A"	n/a

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	n/a
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	n/a
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	n/a
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	
"A" x 0.15	n/a
Note: number must be same as shown in Step 2	
Subtract "C"	n/a
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	n/a
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" <b>A</b> "	n/a	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
" <b>D</b> "	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	n/a	
Step 3: Calculate "E", the amount 7.1A that has already been used	of placement capacity under rule	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	n/a	
Notes:		
<ul> <li>This applies to equity securities – not just ordinary securities</li> </ul>		
<ul> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained		
under rule 7.1 (they must be dealt with in Part 1), or for which specific security		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	n/a
Note: number must be same as shown in Step 2	
Subtract "E"	n/a
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	n/a
	Note: this is the remaining placement capacity under rule 7.1A

Г

<sup>+</sup> See chapter 19 for defined terms.